echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Nat Commun: WSX1: A new tumor suppressor for hepatocellular carcinoma

    Nat Commun: WSX1: A new tumor suppressor for hepatocellular carcinoma

    • Last Update: 2021-06-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Hepatocellular carcinoma (HCC), as one of the most common malignant tumors in the world, ranks fifth in cancer-related mortality
    .


    The occurrence and development of HCC is a multi-factor process, in which the genetic and epigenetic changes of regulatory genes will lead to the activation of oncogenes and the inactivation of tumor suppressor genes


    Hepatocellular carcinoma (HCC), as one of the most common malignant tumors in the world, ranks fifth in cancer-related mortality


    Unlike most other malignant tumors, HCC is a disease related to inflammation and immunity , which almost always occurs in the environment of inflamed liver fibrosis or cirrhosis
    .


    It is worth noting that the tightly controlled immune network that detects and eliminates transformed cells is often dysregulated in HCC


    Immune Notably, the detection and elimination of transformed cells is tightly controlled in HCC immune network often offset is noteworthy that the detection and elimination of transformed cells of the immune disorder is often strictly controlled network in HCC

    PD-L1 (programmed death ligand-1) is a key immune checkpoint protein that can bind to PD-1 (programmed death 1 receptor) on T cells and activate co-inhibitory signals, ultimately inhibiting the effect The function of T cells
    .


    Nevertheless, the relative mechanisms of the steady-state regulation of PD-L1 expression and its dysregulation in cancer are still poorly understood, and understanding the relevant regulatory mechanisms of PD-L1 will help to develop more effective treatment strategies



    WSX1 is the receptor subunit of IL-27, which is widely expressed in immune cells and is closely related to immune response, but its function in non-immune cells is still unclear
    .


    WSX1 is the receptor subunit of IL-27, which is widely expressed in immune cells and is closely related to immune response, but its function in non-immune cells is still unclear
    .


    WSX1 is the receptor subunit of IL-27, which is widely expressed in immune cells and is closely related to immune response, but its function in non-immune cells is still unclear


    WSX1 is down-regulated in HCC and is associated with poor patient prognosis

    WSX1 is down-regulated in HCC and is associated with poor patient prognosis

    In this study, the researchers found that WSX1 is highly expressed in human liver cells, but its expression level is down-regulated in HCC cells
    .


    In the NRAS/AKT-derived primary HCC mouse model, the researchers revealed the tumor suppressor effect of WSX1 independent of IL-27 , which mainly relies on the immune surveillance of CD8+ T cells, that is, by reducing tumor PD -Expression of L1 and related CD8+ T cell depletion


    The tumor suppressor effect of WSX1 independent of IL-27 The tumor suppressor effect of WSX1 independent of IL-27


    Mechanism studies have shown that WSX1 down-regulates the expression level of PI3K isoform PI3Kδ through transcription, inactivates AKT and reduces AKT-induced GSK3β inhibition
    .


    The activated GSK3β will further promote the degradation of PD-L1 and eventually cause the reduction of PD-L1



    Related diagrams

    Related diagrams

    All in all, the results of the study revealed that WSX1 is a tumor suppressor, which can enhance the immune surveillance of the liver by blocking the PI3Kδ/AKT/GSK3β/PD-L1 pathway
    .


    The results of this study will also provide insights into the homeostasis regulation of the host immune response and contribute to the development of related cancer immunotherapies


    WSX1 is a tumor suppressor, which can enhance the immune surveillance of the liver by blocking the PI3Kδ/AKT/GSK3β/PD-L1 pathway
    .
    WSX1 is a tumor suppressor, which can enhance the immune surveillance of the liver by blocking the PI3Kδ/AKT/GSK3β/PD-L1 pathway
    .


    Original source:


    Wu, M.
    , Xia, X.
    , Hu, J.
    et al.
    WSX1 act as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-L1 expression.
    Nat Commun 12, 3500 (09 June 2021).

    WSX1 act as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-L1 expression.

     

    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.